Search

Your search keyword '"Hoppenreijs, E"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Hoppenreijs, E" Remove constraint Author: "Hoppenreijs, E"
126 results on '"Hoppenreijs, E"'

Search Results

1. Curation and expansion of human phenotype ontology for defined groups of inborn errors of immunity

3. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

5. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

7. POS0178 GENE SIGNATURE FINGERPRINTS DIVIDE SLE PATIENTS IN SUBGROUPS WITH COMPARABLE BIOLOGICAL DISEASE PROFILES: A MULTICENTRE LONGITUDINAL STUDY

8. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients

9. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis

10. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

11. FRI0457 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY

17. The identification of CCL18 as biomarker of disease activity in localized scleroderma

18. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation

19. Exome sequencing in routine diagnostics:a generic test for 254 patients with primary immunodeficiencies

20. The identification of CCL18 as biomarker of disease activity in localized scleroderma

21. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation

23. An amino acid motif in HLA-DRb1 distinguishes patients with uveitis in juvenile idiopathic arthritis

24. Regarding “Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea”

25. Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study

26. Regarding “Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea”

28. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers

29. Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides

30. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever Registry

33. Disease recurrence in localized scleroderma: A retrospective analysis of 344 patients with paediatric- or adult-onset disease

34. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

35. Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides

37. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register

38. Perspective validation of the eurofever classification criteria for monogenic periodic fevers

39. CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritis

41. Genetic variation inVTCN1(B7-H4) is associated with course of disease in juvenile idiopathic arthritis

42. PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis

43. PReS-FINAL-2335: Preliminary analysis of 85 patients with mevalonate kinase deficiency from the eurofever registry

44. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

46. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

47. OP0297 Trends in Prescription of Biologics and Outcomes of Juvenile Idiopathic Arthritis; Results of the Dutch National Arthritis and Biologicals in Children Register

48. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register

49. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register

50. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

Catalog

Books, media, physical & digital resources